Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

This study tests a combination of two drugs — sintilimab (an immunotherapy drug) and linperlisib (a targeted therapy) — for people with a rare type of blood cancer called extranodal NK/T-cell lymphoma that has come back or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older with confirmed NK/T-cell lymphoma - Your cancer has relapsed or not responded to at least one prior treatment containing asparaginase - Your overall health is adequate (ECOG 0–2) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have previously received PI3K inhibitor therapy - You have another active cancer within the past 5 years - You have aggressive NK-cell leukemia or brain involvement - You have allergies to monoclonal antibodies Talk to your doctor to see if this trial is right for you.